Search | Clinical Trials Finder

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloproliferative Syndromes, Plasma Cell Myeloma, Colon Carcinoma, Adenocarcinoma of Rectum, Soft Tissue Sarcoma, Ewing's Sarcoma, Rhabdomyosarcoma
Interventions: Natural Killer (NK) Cells, ALT803; Biological
Lead sponsor: Brenda Cooper, MD; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Generalized Anxiety Disorder (GAD), Anxiety Disorders
Interventions: Low-Dose Cannabidiol, Placebo Matched to Moderate-Dose Cannabidiol, Moderate-Dose Cannabidiol, Placebo Matched to Low-Dose Cannabidiol; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Neck Pain, Posterior
Interventions: Acupuncture; Other
Lead sponsor: 5 Element Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Jacksonville, Florida

Conditions: Obesity, Childhood Obesity
Interventions: FBT, FBT+Variety; Behavioral
Lead sponsor: The University of Tennessee, Knoxville; Other
Eligibility: 8 Years to 12 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Breast Neoplasms
Interventions: Sham treatment, Healing Touch; Behavioral
Lead sponsor: University of Wisconsin, Milwaukee; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Opiate Addiction
Interventions: Suboxone, CRA, Therapy, CM; Drug · Behavioral
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Tourette Syndrome
Interventions: D-serine, Riluzole, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Elderly Volunteers
Interventions: Nicotinamide Riboside, Placebo; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 65 Years to 80 Years · Female only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
Interventions: Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803, Ventana PD-L1 (SP263 or SP142) assay; Biological · Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adolescent Idiopathic Scoliosis
Interventions: Scoliosis Specific Exercises; Behavioral
Lead sponsor: Texas Scottish Rite Hospital for Children; Other
Eligibility: 10 Years to 17 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 6
States / cities: Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Postpartum Depression (PPD), Alcohol Use, Contingency Management, Problem Solving Therapy
Interventions: Contingency Management & Problem Solving Therapy, Usual Care; Behavioral · Other
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Oesophageal Adenocarcinoma
Interventions: THOR-707, Pembrolizumab, Cetuximab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Duarte, California • Orlando, Florida • Seattle, Washington

Conditions: Advanced Solid Tumors
Interventions: IMC-18F1; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Detroit, Michigan • Cleveland, Ohio

Conditions: Nicotine Dependence
Interventions: Standard treatment, Standard treatment+practice quitting, Very low nicotine cigarettes; Behavioral · Drug
Lead sponsor: Rutgers University; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Autism Spectrum Disorder, Adhd
Interventions: P-ESDM informed caregiver coaching; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 36 Months to 131 Months
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Bladder Cancer
Interventions: Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV), Pembrolizumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoblast, Adipocytes, Bone Density, Osteocalcin, Adiponectin, Mesenchymal Stem Cells
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Pembrolizumab, Pegylated Liposomal Doxorubicin (PLD); Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 3
States / cities: Boston, Massachusetts • Lake Success, New York

Conditions: Opioid Use Disorder, Bloodstream Infection, Osteomyelitis, Endocarditis, Septic Arthritis, Epidural Abscess
Interventions: RETAIN, Unrelated videos; Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: AGS-003-LNG, Carboplatin, Abraxane, Alimta, Cisplatin, Taxol, Radiation Therapy; Biological · Drug · Radiation
Lead sponsor: GU Research Network, LLC; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Ventral Hernia, Ventral Incisional Hernia, Post Operative Pain
Interventions: PT Group, Usual Care; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Heart Failure With Reduced Ejection Fraction
Interventions: Metoprolol Succinate, Beta-Blocker Polygenic Score, Illumina Infinium Global Diversity Array with Enhanced Pharmacogenomics (PGx); Drug · Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Type 2 Diabetes
Interventions: DIO-902, DIO-902 placebo; Drug
Lead sponsor: DiObex; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 12
States / cities: Muscle Shoals, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 9 more

Conditions: Healthy
Interventions: Maya App; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 22 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803

Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder

Acupuncture Relief for Chronic Neck Pain

Families Becoming Healthy Together

Healing Touch and Health-Related Quality of Life in Women With Breast Cancer Receiving Radiation Therapy

Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II)

Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission

Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Scoliosis-Specific Exercises for At-Risk AIS Curves

Maternal Outcomes: Mood, Alcohol Use, and Depressive Symptoms

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy

Evaluation of Learning-Theory-Based Smoking Cessation Strategies

A+ Treatment/Feasibility of Adapted ESDM-informed Caregiver Coaching Delivered Remotely for Children With ASD (Autism Spectrum Disorder) and ADHD (Attention Deficit Hyperactivity Disorder)

Sacituzumab Govitecan Plus EV in Metastatic UC

Effect of Thiazolidinediones on Human Bone

Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer

Retention and Re-Engagement in Treatment for Addiction Following Serious Injection Related Infections (RETAIN)

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

The IMPACT Study: Personalized Physical Therapy for Better Recovery and a Stronger Core After Hernia Surgery

Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score

A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes

Identification of Biomarkers for Stress Vulnerability and Resilience